Respiratory syncytial virus, an ongoing medical dilemma: an expert commentary on respiratory syncytial virus prophylactic and therapeutic pharmaceuticals currently in clinical trials

Lindsay Broadbent, Helen Groves, Michael D. Shields, Ultan F. Power

Research output: Contribution to journalArticlepeer-review

48 Citations (Scopus)
527 Downloads (Pure)

Abstract

As the most important viral cause of severe respiratory disease in infants and increasing recognition as important in the elderly and immunocompromised, respiratory syncytial virus (RSV) is responsible for a massive health burden worldwide. Prophylactic antibodies were successfully developed against RSV. However, their use is restricted to a small group of infants considered at high risk of severe RSV disease. There is still no specific therapeutics or vaccines to combat RSV. As such, it remains a major unmet medical need for most individuals. The World Health Organisations International Clinical Trials Registry Platform (WHO ICTRP) and PubMed were used to identify and review all RSV vaccine, prophylactic and therapeutic candidates currently in clinical trials. This review presents an expert commentary on all RSV-specific prophylactic and therapeutic candidates that have entered clinical trials since 2008.
Original languageEnglish
Pages (from-to)169-178
Number of pages10
JournalInfluenza and Other Respiratory Viruses
Volume9
Issue number4
Early online date09 Jun 2015
DOIs
Publication statusPublished - Jul 2015

Keywords

  • RSV
  • Vaccines
  • Therapeutics
  • Prophylactics
  • Clinical trials

Fingerprint

Dive into the research topics of 'Respiratory syncytial virus, an ongoing medical dilemma: an expert commentary on respiratory syncytial virus prophylactic and therapeutic pharmaceuticals currently in clinical trials'. Together they form a unique fingerprint.

Cite this